GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, announced today that Chairman & Chief Executive Officer David Dodd will participate in Tribe Public's CEO Presentation and Q&A Webinar Event titled "Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy." The webinar is scheduled for 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time on Thursday, May 28, 2026.
As global health authorities grapple with emerging threats, including recent Hantavirus concerns, Dodd emphasized the need for a paradigm shift. "Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches," he said. "GeoVax is focused on advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and help address critical gaps in domestic and global biodefense infrastructure."
The webinar discussion is expected to address the growing importance of platform-based vaccine technologies in infectious disease preparedness; why emerging outbreaks continue to expose vulnerabilities in global response infrastructure; the potential applicability of MVA-based technologies across multiple viral threats, including orthopox and hemorrhagic fever viruses; and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
GeoVax's priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.
Registration for the complimentary Zoom webinar event is available at Ebola-May-2026.TribePublic.com. Once registered, participants may begin submitting questions for GeoVax management to Tribe Public at research@tribepublic.com or submit questions during the live webinar using Zoom's chat feature. Tribe Public Managing Member John F. Heerdink, Jr. will host the event and moderate audience questions.
The importance of this event lies in its focus on building a resilient infectious disease preparedness strategy. As recent outbreaks of Ebola, Marburg, Mpox, and Hantavirus have shown, the world remains vulnerable to emerging viral threats. GeoVax's MVA-based platform technology offers a potential way to address multiple threats with a single vaccine platform, which could streamline manufacturing and response efforts. The discussion will also highlight the need for scalable domestic vaccine manufacturing capabilities, a critical issue highlighted during the COVID-19 pandemic.
For the audience, the implications are significant: better preparedness could mean faster vaccine deployment in future outbreaks, reducing the risk of widespread illness and economic disruption. For the biotechnology industry, the webinar underscores the shift toward platform-based technologies that can be adapted quickly to new pathogens, representing a potential growth area.
